| (Values in U.S. Thousands) | Mar, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 |
| Sales | 32,980 | 13,080 | 6,870 | 6,690 | 5,700 |
| Sales Growth | +152.14% | +90.39% | +2.69% | +17.37% | +10.89% |
| Net Income | -31,030 | -50,040 | -50,130 | -49,810 | -48,740 |
| Net Income Growth | +37.99% | +0.18% | -0.64% | -2.20% | -0.81% |
Verve Therapeutics Inc (VERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31